Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Abstract: An information handling system (IHS) includes a memory having a BIOS, at least one sensor that generates security related data for the IHS, a controller, and one or more I/O drivers. The memory, at least one sensor and controller operate within a secure environment of the IHS; the I/O driver(s) operate outside of the secure environment. The controller includes a security policy management engine, which is executable during runtime of the IHS to continuously monitor security related data generated by the at least one sensor, determine whether the security related data violates at least one security policy rule specified for the IHS, and provide a notification of security policy violation to the BIOS, if the security related data violates at least one security policy rule. The I/O driver(s) include a security enforcement engine, which is executable to receive the notification of security policy violation from the BIOS, and perform at least one security measure in response thereto.

Abstract: The present invention is directed to azabicyclo[4.1.0]heptane compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

Abstract: A system is disclosed herein including a plurality of information handling systems (IHSs) coupled to and managed by a remote management system (RMS). According to one embodiment, each IHS may be configured to monitor data pertaining to the IHS, determine if the data triggers one or more events, and transmit a notification to the RMS if one or more events are triggered. The RMS may be configured to receive a notification transmitted from at least one IHS, select a policy to be applied to one or more of the IHSs based on the received notification, and transmit the selected policy to the one or more IHS s. The one or more IHSs may be further configured to receive the selected policy from the RMS, store the selected policy, and perform actions specified by the selected policy when policy rules specified by the selected policy are violated.

Abstract: Systems and methods for continuous evaluation of workspace definitions using endpoint context. In some embodiments, an Information Handling System (IHS) of a workspace orchestration service may include a processor and a memory coupled to the processor, the memory having program instructions stored thereon that, upon execution by the processor, cause the IHS to: receive context information from a local management agent of a client device; in response to the context information indicating that a current workspace provided via the local management agent is over-privileged, modify a current workspace definition into a modified workspace definition, where the modified workspace definition outlines fewer resources than the current workspace definition; and transmit, to the local management agent, one or more files configured to enable the local management agent to modify the current workspace based upon the modified workspace definition to reduce a number of resources available to a user of the client device.

Abstract: Compounds of Formula I, or a pharmaceutically acceptable salt, solvate or hydrate thereof: (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Abstract: A method and system comprising a processor executing code instructions of a security filewall validation system for inspecting primitive file system operations to detect abnormal file types, abnormal file operation, or abnormal intended result files in violation of a security filewall rule set, a memory for storing the security filewall rule set describing permitted access to file types, file-paths, mounting points, data volume access rules, or data operations relating to the primitive file system operations where the security filewall validation system intercepts an attempted primitive file system operation and the security filewall validation system compares the attempted primitive file system operation including associated arguments indicating file, file location, and intended result to the security filewall rule set.

Abstract: Systems and methods adjust workspaces based on available hardware resource of an IHS (Information Handling System) by which a user operates a workspace supported by a remote orchestration service. A security context and a productivity context of the IHS are determined based on reported context information. A workspace definition for providing access to a managed resource is selected based on the security context and the productivity context. A notification specifies a hardware resource of the IHS that is not used by the workspace definition, such as a microphone or camera that has not been enabled for use by workspaces. A productivity improvement that results from the updated productivity context that includes use of the first hardware resource is determined. Based on the productivity improvement, an updated workspace definition is selected that includes use of the first hardware resource in providing access to the managed resource via the IHS.

Abstract: A secured virtual environment provides access to enterprise data and may be configured remotely while isolated from the operating system of an Information Handling System (IHS). In secured booting of the IHS, references signatures are received via an out-of-band connection to the IHS. The reference signatures specify reference states for components of the IHS. Prior to launching a secured virtual environment, a trusted resource of the IHS, such as embedded controller isolated from the operating system, is queried for updated signatures specifying operating states of the component. The integrity of the IHS is validated based on comparisons of the respective reference signatures and updated signatures. If the integrity of the IHS is validated, a secured virtual environment is configured such that particular user may access the enterprise data according to applicable policies that may be periodically revalidated. The secured virtual environment may then be launched on the IHS.

Abstract: In accordance with embodiments of the present disclosure, an information handling system may include a processor and a program of instructions embodied in computer-readable media and configured to, when read and executed by the processor: responsive to administrator input associated with the information handling system or a second information handling system managed by the information handling system, set user permissions for one or more users with respect to basic input/output system (BIOS) settings of the information handling system or the second information handling system; and in accordance with the user permissions, create keys for securing BIOS settings of the information handling system or the second information handling system.

Abstract: A compound of Formula (I) or (II), for treating or preventing an HCV infection in a subject.

Abstract: Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (I).

Abstract: Systems and methods for agentless remediation and recovery. In an illustrative, non-limiting embodiment, an Information Handling System (IHS) may include a Central Processing Unit (CPU); a Basic Input/Output System (BIOS) coupled to the CPU; a logic controller coupled to the CPU; and a memory coupled to the logic controller, the memory having program instructions stored thereon that, upon execution by the logic controller, cause the IHS to: during a first stage, check an operational state of a plurality of hardware components within the IHS in the absence of any involvement by the CPU or the BIOS; and during a second stage following the first stage, identify a failed hardware component amongst the plurality of hardware components in the absence of any involvement by the CPU or the BIOS.

Abstract: Systems and methods for tamper-proof detection triggering of automatic lockdown using a recoverable encryption mechanism issued from a secure escrow service. In an illustrative, non-limiting embodiment, an Information Handling System (IHS) may include: a processor; a secure storage device coupled to the processor, wherein the secure storage device comprises a container encrypted with a derived container key; and a memory coupled to the processor, the memory including program instructions stored thereon that, upon execution, cause the IHS to: receive a digital certificate from a remote server, wherein the digital certificate includes a public key and, in response to a detection of a tampering event, encrypt the derived container key using the public key.

Abstract: The present invention relates to novel Chromane-Substituted Tetracyclic Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, A?, R2 R3, R4 and R5 are as defined herein. The present invention also relates to compositions comprising a Chromane-Substituted Tetracyclic Compound, and methods of using the Chromane-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient.

Abstract: A low-power image sensor includes a plurality of light-sensitive pixel cells, a plurality of analog-to-digital converters (ADCs) and image processing circuitry. The image sensor can be disposed in multiple semiconductor layers such that the pixel cells are disposed in a first layer and various other components are disposed in the second layer or between the first layer and the second layer. The image sensor is configured such that the analog output of a pixel cell is sampled by a first ADC and a second ADC within respective first and second dynamic ranges, the second dynamic range being greater than the first dynamic range. The first ADC and the second ADC sample the analog output with different sampling resolutions. The digital outputs of the first ADC and the second ADC are subsequently used by an image processor to generate a pixel value for an image frame.

Abstract: A management system manages a plurality of information handling systems by creating custom policies for each information handling system based on information gathered from or about each information handling system indicating, e.g., the user's intent, use, request for usage, security posture, productivity needs, and/or behavior. The management system creates custom policies to avoid unnecessarily impacting a user's productivity.

Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Abstract: The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A?, R2 R3 and R5 are as defined herein. The present invention also relates to compositions comprising at least one Heterocycle-Substituted Tetracyclic Compound, and methods of using the Heterocycle-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient.

Abstract: A first device management system is assigned to have primary responsibility for management of an information handling system. A record of operating characteristics of the information handling system is maintained by a process executing at the information handling system. Primary responsibility for management of the information handling system is transitioned from the first device management system to a second device management system based on rule based analysis of the operating characteristics.